Literature DB >> 28349445

Prophylactic use of octreotide for asparaginase-induced acute pancreatitis.

Sachi Sakaguchi1, Takeshi Higa2, Mitsuyoshi Suzuki3, Junya Fujimura3, Toshiaki Shimizu3.   

Abstract

In the present study, we sought to evaluate the prophylactic use of octreotide for asparaginase-induced acute pancreatitis. We reviewed the medical records of seven patients in two institutions who received prophylactic octreotide for re-administration of asparaginase after asparaginase-induced acute pancreatitis. Three patients completed asparaginase treatment without developing pancreatitis, and four experienced recurrence of pancreatitis. A literature search using PubMed identified four additional patients in whom asparaginase was successfully re-administered with octreotide. Prophylactic use of octreotide may, thus, be warranted for patients who would benefit from re-administration of asparaginase for cancer treatment; however, careful observation is needed to monitor for breakthrough recurrence of pancreatitis.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Acute pancreatitis; Asparaginase; Octreotide; Prophylaxis

Mesh:

Substances:

Year:  2017        PMID: 28349445     DOI: 10.1007/s12185-017-2219-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  8 in total

1.  Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?

Authors:  Sadao Tokimasa; Kazumi Yamato
Journal:  Br J Haematol       Date:  2011-12-07       Impact factor: 6.998

2.  Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparaginase-induced pancreatitis.

Authors:  Mitsuyoshi Suzuki; Oto Takata; Sachi Sakaguchi; Junya Fujimura; Masahiro Saito; Toshiaki Shimizu
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

3.  Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.

Authors:  Larry W Buie; Joseph Moore; Hank van Deventer
Journal:  Pharmacotherapy       Date:  2014-08       Impact factor: 4.705

4.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Authors:  L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

Review 5.  Asparaginase-associated pancreatitis in children.

Authors:  Raheel Altaf Raja; Kjeld Schmiegelow; Thomas Leth Frandsen
Journal:  Br J Haematol       Date:  2012-08-22       Impact factor: 6.998

6.  Octreotide prevents L-asparaginase-induced pancreatic injury in rats.

Authors:  Mitsuyoshi Suzuki; Toshiaki Shimizu; Takahiro Kudo; Hiromichi Shoji; Yoshikazu Ohtsuka; Yuichiro Yamashiro
Journal:  Exp Hematol       Date:  2007-11-26       Impact factor: 3.084

7.  Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Authors:  Andrew E Place; Kristen E Stevenson; Lynda M Vrooman; Marian H Harris; Sarah K Hunt; Jane E O'Brien; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Steven E Lipshultz; Jeffery L Kutok; Traci M Blonquist; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316

8.  Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.

Authors:  Shu-Fen Wu; An-Chyi Chen; Ching-Tien Peng; Kang-Hsi Wu
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

  8 in total
  2 in total

Review 1.  Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.

Authors:  David O Riley; Jenna M Schlefman; Hans Christoph Vitzthum Von Eckstaedt V; Amy L Morris; Michael K Keng; Firas El Chaer
Journal:  Curr Hematol Malig Rep       Date:  2021-05-12       Impact factor: 3.952

Review 2.  Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy.

Authors:  Krishna R Juluri; Chloe Siu; Ryan D Cassaday
Journal:  Blood Lymphat Cancer       Date:  2022-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.